Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 25 versus DEXTROSE 38 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 25 versus DEXTROSE 38 5 IN PLASTIC CONTAINER.
DEXTROSE 25% vs DEXTROSE 38.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose (D-glucose) is a monosaccharide that provides caloric support. It is transported into cells via glucose transporters (GLUTs) and undergoes glycolysis to produce ATP. It increases blood glucose levels, providing substrate for cellular metabolism.
Dextrose is a simple sugar that provides caloric support and serves as a source of energy. It increases blood glucose levels, which is essential for cellular metabolism, particularly in the brain and erythrocytes.
Adults: 25 grams (100 mL of 25% solution) intravenously as a single dose for hypoglycemia. May repeat if needed based on blood glucose monitoring.
Intravenous administration. Dose depends on clinical condition; typically 50-100 mL of 38.5% dextrose (19.25-38.5 g glucose) for hypoglycemia. Maximum infusion rate: 0.5 g/kg/h.
None Documented
None Documented
Terminal half-life is approximately 30-60 minutes due to rapid cellular uptake and metabolism. Clinical context: In hyperinsulinemic states or insulin therapy, half-life is shortened; in renal/hepatic impairment, half-life may be prolonged but glucose is quickly cleared.
~30 minutes (endogenous glucose turnover; clinical context: continuous infusion required for maintenance as glucose is rapidly metabolized)
Dextrose is completely metabolized to carbon dioxide and water. Excretion: Renal (0% unchanged), Biliary/Fecal (negligible). Essentially 100% metabolized.
100% renal (excreted as carbon dioxide and water after metabolism; negligible unchanged glucose in urine under normoglycemia; renal threshold ~180 mg/dL)
Category C
Category C
IV Fluid
IV Fluid